1198615-84-7 Usage
Description
Ethyl 3-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate is an organic compound that serves as a key intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique chemical structure, which includes a boron-containing 1,3,2-dioxaborolane group and a phenyl ring, making it a versatile building block in the development of new drugs and therapies.
Uses
Used in Pharmaceutical Industry:
Ethyl 3-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate is used as a reagent for the preparation of N-(3-amino-2-hydroxypropyl)benzenesulfonamide and N-(3-amino-2-hydroxypropyl)thiophenesulfonamide derivatives. These derivatives are important in the development of calcium-sensing receptor antagonists and parathyroid hormone (PTH) secretion promoters, which have potential applications in the treatment of various medical conditions related to calcium metabolism and parathyroid function.
Check Digit Verification of cas no
The CAS Registry Mumber 1198615-84-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,8,6,1 and 5 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1198615-84:
(9*1)+(8*1)+(7*9)+(6*8)+(5*6)+(4*1)+(3*5)+(2*8)+(1*4)=197
197 % 10 = 7
So 1198615-84-7 is a valid CAS Registry Number.
1198615-84-7Relevant articles and documents
Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis
Scott, Jill M.,Baccei, Christopher,Bain, Gretchen,Broadhead, Alex,Evans, Jilly F.,Fagan, Patrick,Hutchinson, John H.,King, Christopher,Lorrain, Daniel S.,Lee, Catherine,Prasit, Peppi,Prodanovich, Pat,Santini, Angelina,Santini, Brian A.
scheme or table, p. 6608 - 6612 (2011/12/04)
Biphenylacetic acid (5) was identified through a library screen as an inhibitor of the prostaglandin D2 receptor DP2 (CRTH2). Optimization for potency and pharmacokinetic properties led to a series of selective CRTH2 antagonists. Compounds demonstrated potency in a human DP2 binding assay and a human whole blood eosinophil shape change assay, as well as good oral bioavailability in rat and dog, and efficacy in a mouse model of allergic rhinitis following oral dosing.
